Drug intelligence / Profile preview

maranmicin

Development stage: Unknown
Lead developer: AGILeBiotics
Modality: RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Unknown (not Specified In Public Sources; Likely Parenteral Based On Class)

Overview

Maranmicin is a novel aminoglycoside antibiotic developed by AGILeBiotics. It is being investigated primarily for the treatment of infectious diseases, with a focus on nontuberculous mycobacterial infections and cystic fibrosis-related infections. As an aminoglycoside, its mechanism of action likely involves inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to misreading of mRNA and disruption of bacterial cell function. Maranmicin has reached early phase 1 clinical development in the Netherlands for these indications[1][3][4].

Targets

Bacterial Ribosome

Beyond the preview

Go deeper on maranmicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on maranmicin.

Explore the full profile